Cost-utility analysis of adjuvant trastuzumab therapy for HER2-positive early-stage breast cancer in the Philippines

BACKGROUND: Breast cancer is the leading malignancy among Filipino women, with about 23.50% of cases characterized by human epidermal growth factor receptor-2 (HER2) overexpression. Trastuzumab, in addition to standard chemotherapy, is currently recommended as primary treatment for HER2-positive ear...

Descripción completa

Detalles Bibliográficos
Autores principales: Genuino, Anne Julienne, Chaikledkaew, Usa, Guerrero, Anna Melissa, Reungwetwattana, Thanyanan, Thakkinstian, Ammarin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6873585/
https://www.ncbi.nlm.nih.gov/pubmed/31752849
http://dx.doi.org/10.1186/s12913-019-4715-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6873585/
https://www.ncbi.nlm.nih.gov/pubmed/31752849
http://dx.doi.org/10.1186/s12913-019-4715-8

Ejemplares similares